Anthrax Vaccine Absorbed

Added: Jun 21, 2016 12:52 pm NOTICE OF INTENET TO SOLE SOURCE: The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm fixed price contract to Emergent Biodefense Operations Lansing LLC.

The Government intends to purchase 29,489,780 doses of Food And Drug Administration (FDA) licensed Anthrax Vaccine Absorbed (AVA, also known as Biothrax) by September 23, 2016 with a period of performance of 5 years from Emergent. Emergent is the only FDA licensed provider of AVA and therefore is the only source capable to provide this requirement to the Government. Emergent's manufacturing processes have been validated and are approved by the FDA, (STN 103821, License #1755). The Government intends to negotiate this requirement under the authority of FAR 6.302-1. It is the Government's belief that only one responsible source exists and no other product or services will satisfy agency requirements.

This notice of intent is not a request for competitive proposals. A determination to compete this procurement based on a response to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement should submit a capability statement demonstrating their abilities to meet this requirement. All responses must be received by July 4, 2015 at 12PM Eastern Standard Time. All responses must be in writing and can be sent via email to iom2@cdc.gov . No phone calls will be accepted.